Stable gene expression by self-complementary adeno-associated viruses in human MSCs

Biochemical and Biophysical Research Communications

Volumn 360, Issue 3, 2007, Pages 573-579

  Kim, Sung Jin ^a   Lee, Won Il ^a   Heo, Hwon ^b   Shin, Ohkyu ^a   Kwon, Yunhee Kim ^b   Lee, Heuiran ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

Differentiation; Mesenchymal stem cell; Self complementary rAAV; Serotypes; Transduction efficiency

Indexed keywords

ADENO ASSOCIATED VIRUS; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA MODIFICATION; EMBRYO; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; UMBILICAL CORD BLOOD;

ANTIGENS, CD; CELL DIFFERENTIATION; CELLS, CULTURED; DEPENDOVIRUS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOPHENOTYPING; MESENCHYMAL STEM CELLS; OSTEOBLASTS; TRANSGENES;

ADENO-ASSOCIATED VIRUS; RATTUS;

EID: 34447257463     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.06.081     Document Type: Article

References (31)

1. Oreffo R.O., Cooper C., Mason C., and Clements M. Mesenchymal stem cells: lineage, plasticity, and skeletal therapeutic potential. Stem Cell Rev. 1 (2005) 169-178
2. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., and Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science 284 (1999) 143-147
3. Wislet-Gendebien S., Hans G., Leprince P., Rigo J.M., Moonen G., and Rogister B. Plasticity of cultured mesenchymal stem cells: switch from nestin-positive to excitable neuron-like phenotype. Stem Cells 23 (2005) 392-402
4. Goessler U.R., Riedel K., Hormann K., and Riedel F. Perspectives of gene therapy in stem cell tissue engineering. Cells Tissues Organs 183 (2006) 169-179
5. Horwitz E.M., Prockop D.J., Fitzpatrick L.A., Koo W.W., Gordon P.L., Neel M., Sussman M., Orchard P., Marx J.C., Pyeritz R.E., and Brenner M.K. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med. 5 (1999) 309-313
6. Haberman R.P., Samulski R.J., and McCown T.J. Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat. Med. 9 (2003) 1076-1080
7. Merten O.W., Geny-Fiamma C., and Douar A.M. Current issues in adeno-associated viral vector production. Gene Ther. 12 Suppl. 1 (2005) S51-S61
8. Tal J. Adeno-associated virus-based vectors in gene therapy. J. Biomed. Sci. 7 (2000) 279-291
9. Sanlioglu S., Monick M.M., Luleci G., Hunninghake G.W., and Engelhardt J.F. Rate limiting steps of AAV transduction and implications for human gene therapy. Curr. Gene Ther. 1 (2001) 137-147
10. Carter B.J. Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective. Mol. Ther. 10 (2004) 981-989
11. McCarty D.M., Fu H., Monahan P.E., Toulson C.E., Naik P., and Samulski R.J. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 10 (2003) 2112-2118
12. Wang Z., Ma H.I., Li J., Sun L., Zhang J., and Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther. 10 (2003) 2105-2111
13. Bell P., Wang L., Lebherz C., Flieder D.B., Bove M.S., Wu D., Gao G.P., Wilson J.M., and Wivel N.A. No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol. Ther. 12 (2005) 299-306
14. Grimm D., and Kay M.A. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr. Gene Ther. 3 (2003) 281-304
15. Kern S., Eichler H., Stoeve J., Kluter H., and Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24 (2006) 1294-1301
16. Wu J., Zhao W., Zhong L., Han Z., Li B., Ma W., Weigel-Kelley K.A., Warrington K.H., and Srivastava A. Self-complementary recombinant adeno-associated viral vectors: packaging capacity and the role of rep proteins in vector purity. Hum. Gene Ther. 18 (2007) 171-182
17. Chen S., Kapturczak M., Loiler S.A., Zolotukhin S., Glushakova O.Y., Madsen K.M., Samulski R.J., Hauswirth W.W., Campbell-Thompson M., Berns K.I., Flotte T.R., Atkinson M.A., Tisher C.C., and Agarwal A. Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors. Hum. Gene Ther. 16 (2005) 235-247
18. Chng K., Larsen S.R., Zhou S., Wright J.F., Martiniello-Wilks R., and Rasko J.E. Specific adeno-associated virus serotypes facilitate efficient gene transfer into human and non-human primate mesenchymal stromal cells. J. Gene Med. 9 (2007) 22-32
19. McMahon J.M., Conroy S., Lyons M., Greiser U., O'Shea C., Strappe P., Howard L., Murphy M., Barry F., and O'Brien T. Gene transfer into rat mesenchymal stem cells: a comparative study of viral and nonviral vectors. Stem Cells Dev. 15 (2006) 87-96
20. LEE H.S. Efficient gene expression by self-complementary adeno-associated virus serotypes 2 and 5 in various human cacer cells. Oncol. Rep. (2007)
21. Yang S.E., Ha C.W., Jung M., Jin H.J., Lee M., Song H., Choi S., Oh W., and Yang Y.S. Mesenchymal stem/progenitor cells developed in cultures from UC blood. Cytotherapy 6 (2004) 476-486
22. Kurozumi K., Nakamura K., Tamiya T., Kawano Y., Ishii K., Kobune M., Hirai S., Uchida H., Sasaki K., Ito Y., Kato K., Honmou O., Houkin K., Date I., and Hamada H. Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol. Ther. 11 (2005) 96-104
23. Monahan P.E., and Samulski R.J. AAV vectors: is clinical success on the horizon?. Gene Ther. 7 (2000) 24-30
24. Russell D.W. AAV loves an active genome. Nat. Genet. 34 (2003) 241-242
25. Kay M.A., and Nakai H. Looking into the safety of AAV vectors. Nature 424 (2003) 251
26. McPhee S.W., Janson C.G., Li C., Samulski R.J., Camp A.S., Francis J., Shera D., Lioutermann L., Feely M., Freese A., and Leone P. Immune responses to AAV in a phase I study for Canavan disease. J. Gene Med. 8 (2006) 577-588
27. Wagner J.A., Nepomuceno I.B., Messner A.H., Moran M.L., Batson E.P., Dimiceli S., Brown B.W., Desch J.K., Norbash A.M., Conrad C.K., Guggino W.B., Flotte T.R., Wine J.J., Carter B.J., Reynolds T.C., Moss R.B., and Gardner P. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum. Gene Ther. 13 (2002) 1349-1359
28. Summerford C., and Samulski R.J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72 (1998) 1438-1445
29. Kaludov N., Brown K.E., Walters R.W., Zabner J., and Chiorini J.A. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. 75 (2001) 6884-6893
30. Walters R.W., Yi S.M., Keshavjee S., Brown K.E., Welsh M.J., Chiorini J.A., and Zabner J. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J. Biol. Chem. 276 (2001) 20610-20616
31. Kennell J.A., and MacDougald O.A. Wnt signaling inhibits adipogenesis through beta-catenin-dependent and -independent mechanisms. J. Biol. Chem. 280 (2005) 24004-24010